Key Insights• According to the research report, "Spain Diabetes Care Devices Market Outlook, 2031," published by Actual Market Research, the Spain Diabetes Care Devices Market is expected to reach a market size of more than 1.57 Billion by 2031.• The Spanish diabetes care devices market operates within the framework of the National Health System (Sistema Nacional de Salud - SNS), which provides universal healthcare managed across 17 Autonomous Communities (Comunidades Autónomas). Public funding for Continuous Glucose Monitoring (CGM) and Automated Insulin Delivery (AID) platforms has expanded significantly following portfolio updates by the Ministry of Health (Ministerio de Sanidad). Initially restricted to pediatric populations and high-risk Type 1 diabetes patients, real-time CGMs (rtCGM) and intermittently scanned CGMs (iscCGM) are broadly reimbursed for all Type 1 diabetes patients and insulin-treated Type 2 diabetes patients undergoing intensive insulin therapy.• Because healthcare administration is decentralized across Spain’s 17 autonomous regions (such as Catalonia, Madrid, Andalusia, and the Basque Country), medical device procurement and formulary listings are governed locally by regional health services (Servicios Regionales de Salud). A key technological and operational breakthrough in Spain is the integration of cloud-connected diabetes hardware with regional electronic health record (EHR) platforms and hospital-based diabetology units (Unidades de Diabetología). Factory-calibrated sensors transmit Ambulatory Glucose Profile (AGP) and Time-in-Range (TIR) metrics directly to regional tele-health systems, allowing hospital specialists and primary care teams (Atención Primaria) to manage complex insulin-dependent patients remotely without requiring frequent in-person clinical visits.• Data from the International Diabetes Federation (IDF) and the Spanish Diabetes Society (Sociedad Española de Diabetes - SED) indicate that over 5.1 million adults (aged 20-79) in Spain live with diabetes, reflecting an adult prevalence rate of approximately 14.8% one of the highest rates in Western Europe. Beyond diagnosed cases, an estimated 1.5 million adults remain undiagnosed, while over 4.5 million present with Impaired Fasting Glucose (IFG) or prediabetes.

Type 1 diabetes affects more than 90,000 individuals across Spain, including approximately 15,000 children and adolescents.Market Outlook• The forward-looking landscape for diabetes care devices in Spain focuses on shifting routine monitoring and device access from tertiary hospital specialty clinics down to primary care centers (Centros de Salud) and local community pharmacies. As regional health services aim to alleviate clinical backlogs in hospital diabetology departments, upcoming policies emphasize enabling primary care physicians (médicos de familia) and certified nursing teams to prescribe and support continuous sensors, smart insulin pen accessories, and connected injectors for Type 2 diabetes populations.• Medical device approvals, CE marking verification, and sanitary safety are regulated nationally by the Spanish Agency for Medicines and Medical Devices (Agencia Española de Medicamentos y Productos Sanitarios - AEMPS), while coverage parameters are defined by the Ministry of Health (Ministerio de Sanidad). Scientific research, clinical guidelines, and patient advocacy are championed by leading organizations including the Spanish Diabetes Society (Sociedad Española de Diabetes - SED), the Spanish Federation of Diabetes (Federación Española de Diabetes - FEDE), and the Spanish Society of Endocrinology and Nutrition (SEEN). Major medical technology companies actively leading the commercial market in Spain include Abbott Laboratories España, Dexcom Spain, Medtronic Ibérica, Insulet Spain, Roche Diabetes Care España, Ypsomed España, and Ascensia Diabetes Care Spain.Market DynamicsDriver: Universal public reimbursement under the SNS and autonomous community coverage expansionThe primary growth driver for the Spanish diabetes care devices market is the universal public health coverage provided by the National Health System (Sistema Nacional de Salud - SNS) and its progressive expansion of continuous glucose monitoring (CGM) reimbursement. Managed through the health services of Spain’s 17 Autonomous Communities (Comunidades Autónomas), public funding for continuous sensors (such as Abbott’s FreeStyle Libre and Dexcom’s platforms) and Automated Insulin Delivery (AID) systems has broadened substantially beyond pediatric Type 1 diabetes populations. National coverage directives now encompass all Type 1 diabetes patients as well as insulin-treated Type 2 diabetes patients undergoing intensive insulin therapy who experience severe or unpredicted hypoglycemia.Challenge: Regional procurement fragmentation, autonomous tendering bottlenecks, and budgetary capsDespite overarching SNS funding mandates, device manufacturers face significant operational challenges due to the decentralized structure of Spain's 17 autonomous health services (e.g., Servicio Madrileño de Salud, CatSalut in Catalonia, and Servicio Andaluz de Salud).

Each Autonomous Community independently manages its health budgets, regional drug and device formularies, and public procurement tenders. Consequently, gaining national market authorization does not guarantee uniform patient access; manufacturers must navigate 17 distinct regional tendering processes, each with unique pricing caps, technical evaluation criteria, and delivery timelines.Trend: Migration to primary care management and integrated regional tele-diabetology networksA major trend defining the Spanish market is the decentralization of routine diabetes monitoring from overcrowded hospital specialty units (Unidades de Diabetología) down to primary care health centers (Centros de Salud) and regional digital care platforms. Historically, advanced medical devices were initiated and managed exclusively by hospital-based endocrinologists. However, regional health services are increasingly empowering primary care physicians (médicos de familia) and specialized diabetes nurses to initiate, prescribe, and monitor continuous sensors and smart insulin pen accessories for Type 2 diabetes populations.Segment AnalysisSpain Diabetes Care Devices By Product Type• The Spanish blood glucose monitoring systems market is shaped by the country's publicly funded healthcare system and the role of autonomous communities in organizing healthcare services and device provision. Traditional blood glucose meters, test strips, and lancets remain important for routine testing and backup measurements, while continuous glucose monitoring systems provide more detailed insight into glucose variations throughout the day. Access to advanced monitoring technologies is influenced by clinical eligibility, public reimbursement arrangements, and regional implementation practices.

This makes dependable supply of consumables, affordability, and integration with local healthcare workflows important alongside sensor accuracy and ease of use.• The Spanish insulin delivery devices market includes conventional syringes, insulin pens, insulin pumps, and automated insulin delivery systems that connect insulin administration with glucose monitoring. Pens remain practical for many patients because they are portable and straightforward to use, while pump-based systems offer more flexible dosing and can reduce the burden of manual insulin adjustments for eligible users. A distinctive characteristic of Spain is the decentralized organization of its National Health System, which means regional health services play an important role in implementing procurement, specialist care, and access pathways for advanced technologies.Spain Diabetes Care Devices By Disease Type• The Spanish type 1 diabetes care devices segment is characterized by the need for continuous glucose monitoring, accurate insulin administration, and coordinated specialist support. Continuous glucose monitors, insulin pumps, and automated insulin delivery systems help patients manage glucose fluctuations associated with meals, physical activity, sleep, and illness. Public healthcare coverage for eligible technologies is an important market driver, although access pathways and implementation can differ across autonomous communities. Diabetes specialist teams play a central role in device selection, patient education, and ongoing treatment optimization.

Manufacturers can differentiate through integrated sensor-and-pump platforms, customizable alerts, discreet wearable designs, and reliable supplies of sensors and infusion sets.• The Spanish type 2 diabetes care devices segment serves patients with varied treatment needs, from those managing glucose through lifestyle changes and oral medications to individuals requiring intensive insulin therapy. Blood glucose meters remain useful for routine testing, while continuous glucose monitoring systems can provide additional insight into daily glucose patterns for eligible patients. The market is influenced by public healthcare coverage, clinical prescribing practices, and the ability of primary care professionals to incorporate monitoring technology into routine diabetes management. Spain Diabetes Care Devices By End User • The Spanish home and self-care segment is driven by the need for patients to monitor glucose and manage treatment independently between clinical appointments. Blood glucose meters, continuous glucose monitors, insulin pens, and wearable pumps support daily diabetes management, while connected applications can help users share readings with healthcare professionals and caregivers. Public provision of eligible monitoring supplies and insulin administration equipment supports home-based care, although access to advanced technologies depends on clinical indications and applicable reimbursement arrangements. Retail pharmacies and other distribution channels play an important role in maintaining access to recurring consumables and providing practical device guidance.• The Spanish hospital segment is important for glucose monitoring during acute illness, inpatient treatment, surgery, and the initiation of advanced diabetes therapies.

Point-of-care glucose meters support timely clinical decisions, while insulin delivery systems and professional glucose monitoring technologies are used according to patients' needs and institutional protocols. Hospital procurement is influenced by regional health service budgets, purchasing arrangements, clinical requirements, and the availability of staff trained to use advanced devices. Hospitals and specialist diabetes units also help determine which patients may benefit from insulin pumps or integrated monitoring systems, provide initial education, and coordinate follow-up after discharge.• The Spanish diagnostic centers segment supports diabetes screening, glucose assessment, and clinical evaluation of patients who need further investigation or treatment review. Laboratory testing and point-of-care glucose measurements remain relevant to diagnostic workflows, while professional continuous glucose monitoring can provide additional insight into glucose fluctuations for selected patients. These facilities prioritize reliable equipment, standardized testing procedures, efficient reporting, and timely communication with referring physicians. Their role differs from that of specialist diabetes clinics: diagnostic centers primarily support assessment and reporting, whereas specialist clinics may also initiate device-based treatment and provide ongoing diabetes education.• The Spanish ambulatory surgical centers segment has specific diabetes device requirements because glucose management must be coordinated with preoperative fasting, anesthesia, outpatient procedures, and postoperative recovery.

Point-of-care glucose meters help clinical teams assess glucose levels around surgery, while insulin administration must follow the patient's treatment needs and established perioperative protocols. These facilities prioritize dependable measurements, straightforward equipment operation, clear documentation, and staff familiarity with diabetes-related risks.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Diabetes Care Devices Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product Type• Blood Glucose Monitoring Systems• Insulin Delivery DevicesBy Disease Type• Type 1 Diabetes• Type 2 DiabetesBy End User• Home/Self-Care• Hospitals• Diagnostic Centers• Ambulatory Surgical Centers.